AstraZeneca boss says firm takes China probe ‘very seriously’
The group’s shares have tumbled after it emerged that the firm’s China president has been detained as Chinese authorities deepen their investigation.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The boss of AstraZeneca has said the group takes the probe in China that saw the detention of its president in the country “very seriously” as the drugs giant hiked its financial outlook once again.
AstraZeneca’s shares have been sent reeling after it emerged that Chinese authorities had deepened their investigation into the business.
The group revealed last week that its China president, Leon Wang, has been detained and that two former and two current executives were under investigation in the country over allegations of illegally importing cancer drugs.
Shares in the FTSE 100 listed firm have plunged 10% in the past week on the revelations, with the group quickly losing its coveted £200 billion stock market valuation that it achieved just three months ago.
In its third quarter update on Tuesday, chief executive Pascal Soriot said: “We take the matters in China very seriously.
“If requested we will fully co-operate with the authorities.
“We remain committed to delivering innovative life-changing medicines to patients in China.”
AstraZeneca added that “to the best of the company’s knowledge, the investigations include allegations of medical insurance fraud, illegal drug importation and personal information breaches”, but said it had not received notification that the company itself was being investigated.
The investigation has overshadowed a strong financial performance from the group, which has now upgraded its outlook for second time this year.
The company said it now expects a “high teens” percentage growth in revenue and earnings per share, up from previous guidance for “mid teens”, thanks to booming demand for its blockbuster cancer medicines.
It also revealed a plan to invest 3.5 billion US dollars (£2.7 billion) in research and development and manufacturing in the US business by the end of 2026.
This includes two billion dollars (£1.6 billion) of new investment, with the group ramping up expansion of its US business, which made up 44% of global revenues in the third quarter.
The guidance hike followed forecast-beating third quarter results, with revenues up 21% on a constant currency basis to 13.57 billion dollars (£10.59 billion), boosted by demand for its cancer drugs Imfinzi, Tagrisso and Calquence.